高级检索

基于滚环扩增的核酸载体靶向递送化疗药物的研究

Targeted delivery of chemotherapeutic drugs by nucleic acid carrier based on rolling circle amplification

  • 摘要: 化疗药物普遍缺乏特异性,开发一种可主动靶向递送化疗药物、对生物体无免疫原性的载体越来越受到人们的关注。本研究通过滚环扩增技术(rolling circle amplification, RCA)将合成的具有串联重复序列的DNA长单链与几条包含适配体AS1411的短链DNA杂交来构筑含有多价适配体的核酸载体(multivalent aptamer, Multi-Apt),利用其双螺旋结构大量负载抗肿瘤药物阿霉素(doxorubicin, Dox),用于靶向治疗小鼠黑色素瘤细胞(B16细胞)。通过琼脂糖凝胶电泳优化了RCA产物与短链的结合比例,利用酶标仪探究了Dox的负载及释放,并采用荧光显微镜、流式细胞术、酶标仪、CCK-8法和划痕实验考察了Multi-Apt-Dox对B16细胞的靶向性和生长抑制情况。实验结果显示,RCA产物与3条短链的最佳物质的量比为1∶50。荧光显微镜照片、流式细胞术和酶标仪实验结果表明,每个Multi-Apt可负载约200个Dox分子,而且其对B16细胞的亲和性是单价适配体的46倍。细胞实验表明,Multi-Apt在细胞内降解并释放药物后诱导产生选择性细胞毒性,从而极大降低Dox对正常细胞的毒性,为肿瘤治疗的靶向给药提供一种新的策略。

     

    Abstract: Chemotherapeutic drugs generally lack specificity, and so the development of a carrier that can actively target delivery of chemotherapy drugs without immunogenicity to organisms has attracted increasing attention. In this work, a multivalent aptamer (Multi-Apt) was constructed by hybridizing a long single-stranded DNA (ssDNA) with tandem repeated sequences synthesized by rolling circle amplification (RCA) with several ssDNA encoding aptamer AS1411 sequences. The double-helix structure was used to load the anti-tumor drug doxorubicin (Dox) for targeted treatment of B16 cells. The binding ratio of RCA product to ssDNA was optimized by agarose gel electrophoresis, and the loading and release of Dox were explored using a microplate reader. The targeting and growth inhibition of Multi-Apt-Dox on B16 cells were investigated by fluorescence microscopy, flow cytometry, microplate reader, CCK-8 assay and wound healing assay. The results showed that the optimal molar ratio of RCA product to ssDNA was 1:50. Fluorescence microscopic pictures, flow cytometry analysis and microplate reader experimental results showed that each Multi-Apt could load approximately 200 Dox molecules, and the affinity of Multi-Apt for B16 cells was 46-fold higher than that of free AS1411. Cell experimental results demonstrated that Multi-Apt induced selective cytotoxicity after intracellular degradation and drug release, thereby greatly reducing the adverse reactions of Dox to normal cells and providing a new strategy for targeted drug delivery in tumor treatment.

     

/

返回文章
返回